Can a blood thinner protect Kids' hearts after kawasaki? small study aims to find out
NCT ID NCT06978439
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This pilot study tests the blood thinner Rivaroxaban in 10 Chinese children who developed giant coronary artery aneurysms after Kawasaki disease. The goal is to see if a specially adjusted dose can prevent new blood clots in the heart arteries while keeping bleeding risks low. Children will be followed for at least 6 months to track clots, major heart events, and any bleeding problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rivaroxaban (Xarelto), a blood thinner
What this could lead to
If successful, this could point toward a safe and effective dosing strategy for Rivaroxaban to prevent dangerous blood clots in children with giant coronary artery aneurysms after Kawasaki disease.
What could go wrong
This is a very small pilot study with only 10 children, so results may not apply to all patients. The main risk is bleeding, which can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAWASAKI DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, 201102, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••